The mainstay of systemic therapy for patients with metastatic ER/PR+ breast cancer involves therapies that either antagonize estrogen binding to the ER, suppress and downregulate the ER or block estrogen biosynthesis. This evidence concerns the gene ESR1 and breast cancer.